CEL-SCI

CEL-SCI CROIC

The Cash Return on Invested Capital (CROIC) of CEL-SCI (CVM) as of Oct 30, 2026 is -67.71 %. In the previous year, Cash Return on Invested Capital (CROIC) was -77.20 % — a change of -12.30% (higher).

CROIC

-67.71 %

YoY

-12.30%

Last updated:

Cash Return on Invested Capital (CROIC) of CEL-SCI is 2025 -67.71 % . Cash Return on Invested Capital (CROIC) of CEL-SCI was 2024 -77.20 % . It decreases by -12.30% higher compared to the previous year.

The CEL-SCI CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
-94.54 USD
Jan 1, 2019
-88.76 USD
Jan 1, 2020
-53.38 USD
Jan 1, 2021
-38.38 USD
Jan 1, 2022
-39.77 USD
Jan 1, 2023
-86.69 USD
Jan 1, 2024
-77.20 USD
Jan 1, 2025
-67.71 USD
The CEL-SCI CROIC history
YEARCROICYoY
-67.71 %-12.30%
-77.20 %-10.94%
-86.69 %+117.96%
-39.77 %+3.64%
-38.38 %-28.11%
-53.38 %-39.85%
-88.76 %-6.12%
-94.54 %-25.59%
-127.05 %-32.34%
-187.76 %-30.86%
-271.55 %+36.15%
-199.45 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CEL-SCI Stock analysis

What does CEL-SCI do? CEL-SCI Corp develops immunotherapies targeting cancer and infectious diseases, focusing on Multikine for head and neck cancers and anal warts in HIV/HPV co-infected patients, and L.E.A.P.S. technology for influenza and rheumatoid arthritis treatments. The company generates revenue through research and development services, with products like LEAPS-H1N1-DC and CEL-2000/CEL-4000 in clinical development. Its primary customers are pharmaceutical partners and research institutions seeking novel therapeutic solutions. The firm operates within the biotechnology sector, emphasizing immune system activation for disease treatment. Multikine and L.E.A.P.S. therapies represent CEL-SCI's core product pipeline, with Multikine targeting head and neck cancers and cervical dysplasia, while L.E.A.P.S. focuses on pandemic influenza and rheumatoid arthritis. The company monetizes its R&D efforts by advancing these therapies through clinical trials, aiming for partnerships with larger pharmaceutical firms for commercialization. Its segment is defined by the development of investigational drugs and vaccines, with no current commercial products generating direct revenue. CEL-SCI's revenue model relies on securing funding for clinical trials and potential future licensing agreements. The company's focus on immune-based therapies for unmet medical needs attracts interest from biotech investors and collaborative partners. Its product candidates, including LEAPS-H1N1-DC and CEL-2000, are positioned for development into marketable treatments, though no sales have occurred yet. CEL-SCI is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CEL-SCI stock

Cash Return on Invested Capital (CROIC) of CEL-SCI is -67.71 % in 2025.

Cash Return on Invested Capital (CROIC) of CEL-SCI changed from -77.20 % to -67.71 %, representing a -12.30% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) CEL-SCI since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s CEL-SCI with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — CEL-SCI

All Key Metrics — CEL-SCI